All In Biotech

Drug Trial Radar · NCT06657222

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients With Advanced Solid Tumors (5-STAR 1-01)

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Dec 13, 2024

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Oct 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms

Conditions

  • Advanced Solid Tumors
  • HNSCC
  • SCLC
  • NSCLC
  • TNBC - Triple-Negative Breast Cancer
  • CRC

Interventions

  • TUB-030Drug

    A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of MTDTime frame: From enrollment until 30 days after last study drug

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Mount Sinai

    New York, New York · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • NEXT Oncology Austin

    Austin, Texas · Recruiting

  • NEXT Oncology - Dallas

    Irving, Texas · Recruiting

  • NEXT Oncology - San Antonio

    San Antonio, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Princess Margaret

    Toronto, Canada · Recruiting

  • Institut Curie

    Paris, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Not yet recruiting

  • Arensia Exploratory Medicine

    Bucharest, Romania · Recruiting

  • Arensia Exploratory Medicine

    Cluj-Napoca, Romania · Recruiting

  • Hospital Clinic Barcelona

    Barcelona, Spain · Recruiting

  • Clinica Uni de Navara

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.